VantAI
Proxima (formerly VantAI) is a private AI-driven biotech that builds a proximity-modulating therapeutics platform for protein-protein interactions, licensing and co-developing Inducers, Modulators, and Blockers with large pharmaceutical partners such as BMS, JnJ, Blueprint Medicines, and Halda Therapeutics.
- Company typePrivate
- Founded2019
- Headquarters—
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What VantAI does
Proxima (formerly VantAI) is a privately held biotechnology company founded in 2019 that operates an AI-driven drug discovery platform focused on making protein-protein interactions programmable. The company's core offering, the Proxima Discovery Platform, integrates three complementary phase-shifting technologies with an AI drug discovery engine and a proprietary structural proteomics data generation platform to develop proximity-modulating therapeutics classified into Inducers, Modulators, and Blockers. With 51-100 employees, Proxima markets its capabilities to large pharmaceutical and biotech partners and publicly highlights ongoing collaborations with Bristol Myers Squibb, Johnson & Johnson, Blueprint Medicines, and a $1 billion-plus strategic research alliance with Halda Therapeutics centered on next-generation RIPTAC medicines. The company also promotes a product line branded NEO-1 alongside its core platform.
Proxima's business model is enterprise B2B, centered on direct strategic research collaborations and co-development agreements with pharmaceutical counterparties. Revenue is generated through licensing/royalty arrangements attached to these collaborations and through AI platform services rendered to pharma partners, with pricing handled on a bespoke basis rather than through standardized tiers. GTM is executed via direct outreach and partnership inquiries through a dedicated partnership channel, supplemented by thought-leadership initiatives such as a monthly Generative AI in Drug Discovery lecture series, corporate website presence, and active engagement across LinkedIn, X, and GitHub.
The company's go-to-market is reinforced by a Scientific Advisory Board that includes Dr. Raymond Deshaies, Dr. Lyn Jones, and Dr. Juri Rappsilber, lending drug discovery credibility. In January 2026 the company rebranded from VantAI to Proxima and closed an $80 million seed financing round led by DCVC with participation from Nvidia, earmarked for advancing the proximity-modulating therapeutics platform and AI drug discovery capabilities.
VantAI firmographics
Firmographics- Name
- VantAI
- Website
- https://vant.ai
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Proxima (formerly VantAI) is a private AI-driven biotech that builds a proximity-modulating therapeutics platform for protein-protein interactions, licensing and co-developing Inducers, Modulators, and Blockers with large pharmaceutical partners such as BMS, JnJ, Blueprint Medicines, and Halda Therapeutics.
- Ownership category
- akta.pro rank
VantAI industry classification
Industry- Product category
- AI Drug Discovery Platform
- NAICS
- Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Proteomics & Biomarker Analytical Testing (HLAGADAG)
Keywords
VantAI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Strategic Research Collaborations: Proxima generates revenue through strategic research collaborations with pharmaceutical companies, including co-development agreements and licensing arrangements for proximity-based therapeutics. The Halda Therapeutics alliance represents over $1 billion in total potential value.
- AI Platform Services: Revenue from providing AI-powered drug discovery services and data generation capabilities to pharmaceutical partners.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
VantAI product offering
Product offeringCore offering
Proxima (formerly VantAI) provides an AI-driven drug discovery platform focused on proximity-modulating therapeutics that target protein-protein interactions. Its integrated platform combines three complementary phase-shifting technologies, an AI data generation engine, and a structural proteomics data platform to design Inducers, Modulators, and Blockers for therapeutic use. The company monetizes this platform through strategic research collaborations and licensing-style partnerships with pharmaceutical companies.
Product overview
Proxima (formerly VantAI) offers an integrated AI-powered drug discovery platform focused on proximity-modulating therapeutics that target protein-protein interactions. The platform combines three complementary phase-shifting technologies to make protein interactions programmable. The portfolio includes the core Proxima Discovery Platform, the NEO-1 product, and a modality pipeline of proximity Inducers, Modulators, and Blockers. The company leverages advanced AI and structural proteomics data to decode and design interfaces of life for developing next-generation medicines.
Differentiator
Problem solved
Functional benefit
Products and services
- Proxima Discovery Platform An integrated AI-powered discovery platform combining three complementary phase-shifting technologies to develop proximity-modulating therapeutics that target protein-protein interactions, offered to pharmaceutical and biotech partners.
- NEO-1 A product within the Proxima portfolio, referenced as a key offering alongside the main Proxima Discovery Platform.
- Proximity Modulators (Inducers, Modulators, Blockers) Three classes of proximity-modulating therapeutics designed to induce, modulate, or block protein-protein interactions for therapeutic effect, enabled by the Proxima Discovery Platform.
Quantifiable outcome
- Over $1 billion in total potential collaboration value with Halda Therapeutics
Companies that use VantAI
Customer profileNamed customers4 records
Segments1 record
Ideal customer profiles1 record
VantAI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
VantAI partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Halda TherapeuticsflagshipProxima and Halda Therapeutics announced a strategic research collaboration worth over $1 billion in total potential value. The collaboration focuses on discovering next-generation RIPTAC (Regulatory Inducing Protein Targeting And Chimera) medicines using Proxima's proximity therapeutics platform.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
VantAI competitors and assessment
Company assessmentDirect peers
- XtalPi: XtalPi combines AI, quantum physics, and robotics for small-molecule and biologics discovery with multiple pharma partnerships. Directly comparable as an AI drug discovery platform serving global pharma.
- Atomwise: Atomwise uses AI for small-molecule hit discovery and has signed multi-billion-dollar pharma collaborations. Directly comparable to Proxima's AI platform approach serving pharma partners.
- Insitro: Insitro is an AI-driven drug discovery company combining machine learning with high-throughput biology to discover and develop therapeutics. Directly comparable to Proxima's platform-play approach targeting pharma collaborations.
- Isomorphic Labs: Alphabet-backed Isomorphic Labs applies DeepMind's protein-structure and generative AI to drug discovery, with pharma partnerships (Eli Lilly, Novartis). Directly comparable in combining frontier AI with pharma collaborations.
- Halda Therapeutics: Halda Therapeutics is the RIPTAC-focused biotech partnered with Proxima under a $1B+ deal. Directly comparable as a proximity-modulating therapeutics company and Proxima's flagship counterparty.
- Generate Biomedicines: Generate Biomedicines is a generative biology platform designing novel proteins and therapeutics, with major pharma partnerships (e.g., Amgen, Novartis). Closely comparable to Proxima's protein-design and AI-discovery angle.
- Recursion Pharmaceuticals: Recursion is a publicly listed AI-enabled drug discovery platform combining high-throughput wet-lab experimentation with machine learning. Closely comparable to Proxima in applying AI/ML to pharma R&D and pursuing enterprise partnerships.
Broad incumbents
- Arvinas: Arvinas is a publicly traded leader in targeted protein degradation (PROTACs), a related proximity-modulating modality. Comparable as a broader incumbent in proximity-based therapeutic modalities.
Emerging players
- EvolutionaryScale: EvolutionaryScale focuses on large generative models for protein design, with notable AI talent pedigree. Comparable as an emerging AI-protein platform, though more focused on foundation-model development than pharma BD today.
- Cradle Bio: Cradle applies generative AI to protein engineering and biologics design, working with biotech and pharma partners. Comparable in using AI for protein-centric drug discovery, though smaller and earlier stage than Proxima.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
VantAI social profiles
Digital presenceVantAI financial estimates
Financial estimateRevenue estimate
Valuation estimate
VantAI leadership team
Management profileNumber of profiles
Profiles3 records
VantAI funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VantAI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VantAI
What does VantAI do?
Proxima (formerly VantAI) provides an AI-driven drug discovery platform focused on proximity-modulating therapeutics that target protein-protein interactions. Its integrated platform combines three complementary phase-shifting technologies, an AI data generation engine, and a structural proteomics data platform to design Inducers, Modulators, and Blockers for therapeutic use. The company monetizes this platform through strategic research collaborations and licensing-style partnerships with pharmaceutical companies.
Is VantAI a public or private company?
VantAI is a private company. It is classified as venture growth investor backed and is currently operating.
When was VantAI founded?
VantAI was founded in 2019. It employs 51 to 100 people.
How does VantAI make money?
Two revenue lines are on record. Strategic Research Collaborations are the primary driver. The others are AI Platform Services.
Who are VantAI's main competitors?
Direct peers on record are XtalPi, Atomwise, Insitro, Isomorphic Labs, Halda Therapeutics, Generate Biomedicines and Recursion Pharmaceuticals. Arvinas is listed as a broad incumbent. Emerging players are EvolutionaryScale and Cradle Bio.
Does VantAI have an API?
No public API is recorded for VantAI.
What industry is VantAI in?
VantAI's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 3345 and its SIC code is 7372.